科伦药业：科伦博泰与Crescent达成战略合作 合同包含8,000万美元的首付款

Core Viewpoint - The company has established a strategic partnership with Crescent Biopharma to jointly develop and commercialize cancer treatment methods, which includes significant financial arrangements and potential future earnings from sales royalties [1] Financial Arrangements - Sichuan Kelun Botai Biopharmaceutical Co., Ltd. will receive an upfront payment of $80 million from Crescent Biopharma [1] - The company is eligible for up to $1.25 billion in milestone payments based on the partnership's success [1] - Additionally, Kelun Botai will receive tiered royalties ranging from mid-single to low-double digits percentage based on the net sales of SKB105 [1] Additional Financial Terms - Crescent Biopharma will pay an upfront fee of $20 million to Kelun Botai and is eligible for up to $30 million in milestone payments [1] - Crescent will also pay tiered royalties based on the net sales of CR-001, starting from low to mid-single digits percentage [1] Control Change Provisions - If there is a change in control at Crescent or if they enter into sublicensing agreements with third parties, Kelun Botai may receive additional payments [1]